GlaxoSmithKline Pharmaceuticals Limited — Investor Meet, 18-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

GSK Pharma reports FY26 revenue up 2%, with EBITDA climbing 11% and PAT 10%, crossing INR 1,000 crore (ex-exceptionals). Q4 sales also rose 2%. Gross margins expanded 190bps, boosting EBITDA ratio to 34%. Growth was muted by resolved supply constraints and delayed vaccine shipments, expected to normalize in Q1 FY27. Management aims for double-digit top-line growth, driven by its innovation portfolio (now 6% of sales, targeting 10%) including new oncology and vaccine launches. A strong pipeline and operational efficiencies underpin a confident outlook for profitable expansion.